Polypoidal Choroidal Vasculopathy: all 54 studies

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal VasculopathyRecruitingNCT07695207Phase 3
• Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal VasculopathyRecruitingNCT07461441Phase 3
• Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS TrialRecruitingNCT07389980Phase 3
• A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)Not yet recruitingNCT07365371Phase 4
• Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)RecruitingNCT06709339Phase 4
• OCT in Rare Chorioretinal DiseasesRecruitingNCT02141308
• An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal VasculopathyCompletedNCT03117634Phase 4Results posted
• Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal VasculopathyStatus unknownNCT02597855Results posted
• A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)CompletedNCT02397954Phase 2Results posted
• Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal VasculopathyCompletedNCT01950741Phase 4Results posted
• Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)CompletedNCT01884597Phase 1/2Results posted
• Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)CompletedNCT01846273Phase 4Results posted
• Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal VasculopathyCompletedNCT01469156Phase 1/2Results posted
• Ranibizumab (Lucentis) for Polypoidal Choroidal VasculopathyCompletedNCT00837330Phase 1/2Results posted
• Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal VasculopathyCompletedNCT00674323Phase 4Results posted
• Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: Pain, Procedure Time, Patient Satisfaction, and SafetyActive, not recruitingNCT07481500Not applicable
• Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal VasculopathyCompletedNCT05666804Phase 3
• Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCVCompletedNCT05662943
• Clinical Implication of Aflibercept in PCV Treatment in ChinaStatus unknownNCT05639660
• Conbercept for Polypoidal Choroidal Vasculopathy（START Study）CompletedNCT05229237
• Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for ExclusionCompletedNCT04836143
• OCTA and Polypoidal Choroidal VasculopathyCompletedNCT04714242
• Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving AfliberceptStatus unknownNCT04707027Not applicable
• Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal VasculopathyStatus unknownNCT04380974Phase 4
• Biomarkers of Common Eye DiseasesStatus unknownNCT04101604
• Treatment of Polypoidal Choroidal Vasculopathy in PachychoroidCompletedNCT04075188Not applicable
• Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV TreatmentCompletedNCT03941587Not applicable
• Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)CompletedNCT03929731
• Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN RegimenCompletedNCT03459144Not applicable
• ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)WithdrawnNCT03374670Phase 2
• The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)Status unknownNCT03159884Phase 4
• Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular DiseasesStatus unknownNCT03128463
• Intraocular Cytokine in Recurrence of Polypoidal Choroidal VasculopathyStatus unknownNCT02976194Phase 4
• Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)CompletedNCT02860858Phase 4
• Genetic Factors of Idiopathic Polypoidal Vasculopathies in the ATM Gene (Ataxia Telangiectasia Mutated)TerminatedNCT02857894
• Initial Versus Delayed PDT Combination With Conbercept in PCVCompletedNCT02821520Phase 4
• Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markersStatus unknownNCT02815176
• Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal VasculopathyStatus unknownNCT02806752Phase 4
• Double-dose Ranibizumab for Polypoidal Choroidal VasculopathyTerminatedNCT02769169Phase 2/3
• Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal VasculopathyCompletedNCT02495181Phase 4
• Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept TreatmentCompletedNCT02381730Not applicable
• Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)Status unknownNCT02092532Phase 4
• Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal VasculopathyCompletedNCT02072408Phase 4
• Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or ExudationCompletedNCT01871376Phase 4
• Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal VasculopathyWithdrawnNCT01666236Phase 4
• Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic TherapyStatus unknownNCT01360151Not applicable
• iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)TerminatedNCT01334255Phase 1
• Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPsCompletedNCT01271426
• Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal VasculopathyStatus unknownNCT01248117Phase 1/2
• Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)CompletedNCT01023295Phase 2
• Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related MaculopathyCompletedNCT00470977Phase 1/2
• Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)CompletedNCT00424710Phase 1
• Intravitreal Bevacizumab for Polypoidal Choroidal VasculopathyStatus unknownNCT00383812Not applicable
• Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous MaculopathyStatus unknownNCT00344617Phase 3

← Polypoidal Choroidal Vasculopathy overview